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Glypican-3 and CD81 Promote Development Of Hepatocellular Carcinoma 
And Hepatoblastoma Through Negative Selection.  
Yuhua Xue, Wendy M. Mars, William Bowen, Aatur D. Singhi, Sarangarajan 
Ranganathan, George K. Michalopoulos* 
Department of Pathology, University of Pittsburgh, PA 15261 
Glypican3  (GPC3) is highly over-expressed in hepatocellular carcinomas  
(HCC). Loss-of-function mutations of Glypican-3 cause organomegaly (Simpson-
Golabi-Behmel syndrome).  GPC3 also down-regulates nuclear Yap and binds to 
CD81. Activation of CD81 by agonistic antibody is associated with activation of 
spleen kinase (Syk) and phosphorylation of Ezrin, a regulator of Hippo pathway. 
The purpose of this study is to explore the role of CD81 and GPC3 protein in 
regulation of the Hippo pathway and Yap and to investigate why does GPC3 
over-expression fail to cause decrease in Yap in HCC, most of which have 
elevated levels of Yap. In cultures of normal hepatocytes, CD81 agonistic 
antibody led to enhanced phosphorylation of Ezrin and increase in nuclear Yap. 
Forced expression of CD81 in a GPC3--expressing HCC cell line caused 
activation of Hippo, decrease in Ezrin phosphorylation and decrease in Yap. 
Overexpression of CD81 associated Syk kinase in the same cell line caused 
inactivation Hippo, increase in Ezrin phosphorylation and increase in Yap. HCC 
tissue microarray revealed lack of expression of CD81 in most HCC. 
Hepatoblastoma tissue microarray also show that CD81 loss membrane 
expression in 56% of cases. 
Conclusions: Activation of CD81 by agonistic antibody results in Hippo pathway 
suppression and increase in nuclear Yap. GPC3 is likely to enhance hepatic 
neoplasia by acting as negative selection “promoter” of growth of early CD81-
negative neoplastic hepatocytes or hepatoblasts which are resistant to GPC 
inhibition effect and thus have a proliferative advantage to clonally expand as 
they participate in the required maintenance of 100% of liver weight 
(“hepatostat”). 
